Background
Patients with moyamoya disease (MMD) have a high risk of stroke or death. We investigated whether extracranial to intracranial bypass surgery can reduce mortality by preventing strokes in patients with MMD.
Methods and Results
This nationwide retrospective cohort study encompassed patients with MMD registered under the Rare Intractable Diseases program via the Relieved Co‐Payment Policy between 2006 and 2019, using the Korean National Health Insurance Service database. Following a 4‐year washout period, landmark analyses were employed to assess mortality and stroke occurrence between the bypass surgery group and the nonsurgical control group at specific time points postindex date (1 month and 3, 6, 12, and 36 months). The study included 18 480 patients with MMD (mean age, 40.7 years; male to female ratio, 1:1.86) with a median follow‐up of 5.6 years (interquartile range, 2.5–9.3; mean, 6.1 years [SD, 4.0 years]). During 111 775 person‐years of follow‐up, 265 patients in the bypass surgery group and 1144 patients in the nonsurgical control group died (incidence mortality rate of 618.1 events versus 1660.3 events, respectively, per 10
5
person‐years). The overall adjusted hazard ratio (HR) revealed significantly lower all‐cause mortality in the bypass surgery group from the 36‐month landmark time point, for any stroke mortality from 3‐ and 6‐month landmark time points, and for hemorrhagic stroke mortality from the 6‐month landmark time point. Furthermore, the overall adjusted HRs for hemorrhagic stroke occurrence were beneficially maintained from all 5 landmark time points in the bypass surgery group.
Conclusions
Bypass surgery in patients with MMD was associated with a lower risk of all‐cause and hemorrhagic stroke mortality and hemorrhagic stroke occurrence compared with nonsurgical control.